Parminder Singh, MD, presented “Neoadjuvant or Adjuvant Therapy?” at the 6th International Bladder Cancer Update on November 18, 2022, in Scottsdale, Arizona.
How to cite: Singh, Parminder. “Neoadjuvant or Adjuvant Therapy?” November 2022. Accessed Nov 2024. https://grandroundsinurology.com/neoadjuvant-or-adjuvant-therapy/
Neoadjuvant or Adjuvant Therapy? – Summary
Parminder Singh, MD, Assistant Professor of Hematology and Oncology at Mayo Clinic in Phoenix, Arizona, discusses the future of care for muscle-invasive bladder cancer (MIBC) in this 14-minute talk. Two large trials–one SWOG trial from 2003 evaluating methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) prior to cystectomy, and an international trial reporting on cisplatin, methotrexate, and vinblastine (CMV) prior to cystectomy or radiation–both famously showed improved survival in MIBC patients. Because of this data, neoadjuvant chemotherapy (NAC) became the gold standard for care. Since then, research in this area has focused on fine-tuning drug options and patient selection under the NAC framework, such as evaluating MVAC versus gemcitabine and cisplatin (GC), options for cisplatin-ineligible patients, and how pathological responses to NAC affect survival. However, Singh suggests this space of MIBC management is ready to move into a new chapter due to antibody-drug conjugates. The current data about these emerging drugs is promising. There is evidence that patients who priorly did not respond to chemotherapy had improvements in overall survival with enfortumab vedotin (EV). Currently, there is a mock trial comparing EV, pembrolizumab, and GC in cisplatin ineligible patients at the Mayo Clinic. Singh is optimistic EV and pembrolizumab may be able to replace cisplatin for those who are ineligible in the future.
About the 6th International Bladder Cancer Update:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Dr. Parminder Singh, MD, is an Assistant Professor of Hematology and Oncology at Mayo Clinic in Phoenix, Arizona, and a Genitourinary oncologist who specializes in bladder cancer with research focus in developing novel therapeutics. He is the Study Chair on SWOG 1806, which is a phase III clinical trial evaluating trimodality therapy in combination with atezolizumab in muscle-invasive bladder cancer.
